LEO Pharma Bets on DTC Push for Hand Eczema Treatment Amidst Low Awareness
Event summary
- LEO Pharma launched a direct-to-consumer (DTC) campaign, 'It’s GO time,' for ANZUPGO (delgocitinib) cream on March 5, 2026.
- ANZUPGO is the first FDA-approved treatment for moderate to severe chronic hand eczema (CHE), approved in July 2025.
- A 2025 survey revealed that only 30% of U.S. patients with hand eczema are aware of the condition, and nearly 75% find their symptoms frustrating to manage.
- The campaign targets a patient population of approximately 1 in 10 adults in the U.S. (roughly 33 million people).
The big picture
LEO Pharma's move into DTC marketing represents a shift in strategy for a traditionally physician-focused pharmaceutical company, reflecting a broader trend towards patient empowerment and direct engagement. The low awareness of CHE, despite its prevalence, highlights a significant unmet need and a potential opportunity for targeted marketing. This campaign underscores the growing importance of patient education in driving adoption of specialized therapies, particularly as competition in the dermatology market intensifies.
What we're watching
- Campaign Efficacy
- The success of the DTC campaign will hinge on its ability to demonstrably increase patient awareness and drive demand for ANZUPGO, which will be reflected in prescription numbers and market share gains.
- Competitive Response
- Other pharmaceutical companies will likely observe LEO Pharma’s DTC strategy and may consider similar approaches for competing treatments or new entrants in the hand eczema space.
- Safety Profile
- Continued scrutiny of ANZUPGO’s safety profile, particularly regarding infection risk and skin cancer, will be crucial, as any adverse event reports could significantly impact adoption and marketing efforts.
Related topics